Volume 194 - Issue 1
Managing residual risk in patients receiving statin therapy
Author: Ian R Hamilton-Craig
Med J Aust 2011; 194 (1): 54. || doi: 10.5694/j.1326-5377.2011.tb04160.x
Published online: 3 January 2011
Published online: 3 January 2011
In reply: In the interests of scientific exactitude, I am indebted to Marilyn Mann for corrections regarding the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial. However, as the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial did not include the control group ezetimibe versus placebo, the effects of ezetimibe on carotid intima media thickness remain somewhat speculative.1
Competing interests
I have served on lipid advisory boards for Merck Sharp and Dohme, Solvay/Abbott and AstraZeneca, and have received speaker fees and reimbursement for travel/accommodation expenses to attend scientific meetings from these companies. I have also received honoraria from these companies and from Novartis, Pfizer, Schering Plough and Servier for presentations at postgraduate scientific meetings.
References
- Stein E. After ENHANCE: is more LDL cholesterol lowering even better? Clin Chem 2008; 54: 940-942. 0_JJJHADGB